On Oct 08, major Wall Street analysts update their ratings for $Zenas BioPharma (ZBIO.US)$, with price targets ranging from $27 to $40.
Morgan Stanley analyst Vikram Purohit initiates coverage with a buy rating, and sets the target price at $40.
Citi analyst Yigal Nochomovitz initiates coverage with a buy rating, and sets the target price at $27.
Jefferies analyst Roger Song initiates coverage with a buy rating, and sets the target price at $35.
Guggenheim analyst Yatin Suneja initiates coverage with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Zenas BioPharma (ZBIO.US)$'s main analysts recently are as follows:
Zenas BioPharma's obexelimab is seen as a significant asset within its portfolio, poised to address various conditions within the inflammation and immunology category. The primary indication, IgG4-RD, is at the forefront. Should the Phase 3 data for IgG4-RD prove positive, it has the potential to set the stage for addressing broader downstream indications.
Initial clinical results for Zenas BioPharma's primary candidate, obexelimab, appear promising. There's potential for this therapy to stand out in terms of safety and effectiveness within substantial inflammation and immunology-related markets. The anticipation of considerable stock appreciation is tied to upcoming Phase II/III developments in 2024 and 2025.
Zenas BioPharma is identified as a late clinical stage biotech firm with a focus on tackling inflammation and immunological challenges. The company's prime asset, obexelimab, is characterized as a 'first-in-class' with a unique inhibitory action for a range of B-cell mediated autoimmune conditions.
Zenas BioPharma's principal product, obexelimab, has the potential to lead its class as an anti-CD19xFcgammaRIIb bifunctional B cell-inhibiting antibody, with ongoing development targeting IgG4-related disease. The current market valuation of the company stands at approximately $480 million, and with several important clinical milestones expected in the next year and a half, there appears to be substantial room for growth in the company's value from its present position.
Here are the latest investment ratings and price targets for $Zenas BioPharma (ZBIO.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
